Hamburg, Germany | Oxford, UK | Glasgow, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today the expansion of its sterile pharmaceutical manufacturing facility in Glasgow, Scotland. The Company has doubled its capacity for the aseptic (sterile) GMP manufacture of pharmaceuticals to be used in clinical trials with the new facility being operational with immediate effect.
 
Evotec's formulations business is a niche provider of contract pharmaceutical development services for the development of formulations of pharmaceuticals intended for parenteral administration and the manufacture of formulated drugs for use in Phase I and Phase II clinical trials. Its client base comprises pharmaceutical and biotechnology companies around the world and it has particular expertise in the development of lyophilised (freeze-dried) formulations and the subsequent sterile manufacture of those formulated drugs. In addition, it has dedicated facilities to assist in the development of cytotoxic (cytotstatic) pharmaceuticals.
 
The expansion of the facilities is in response to the demand from its clients for clinical supplies of liquid and lyophilised drug product. Evotec has demonstrated its expertise in drug formulation development and sterile manufacturing, offering its clients services of the highest quality and technical standards. These additional facilities will allow Evotec to shorten the lead-time to access its manufacturing capabilities and will save its clients time. This will therefore accelerate the progression of Evotec's clients' drugs into the clinical stage of drug development.
 
Contact:
Anne Hennecke, SVP Investor Relations & Corporate Communications, Evotec AG, Phone: +49-40-56081-286, anne.hennecke@evotec.com